Monoamine oxidase inhibitors for treatment-resistant depression

William V. Bobo, Elliott Richelson

Research output: Chapter in Book/Report/Conference proceedingChapter


Monoamine oxidase inhibitors (MAOIs) constitute the oldest class of antidepressants and are efficacious treatments for patients with unipolar major depression and selected anxiety disorders. Despite being highly effective, the clinical use of MAOIs has been limited by waning clinical experience and a poor understanding of dietary restrictions and drug interactions—to the point that they are now rarely prescribed by most psychiatrists. Nevertheless, there has been renewed interest in the clinical use of MAOIs given the high rates of treatment resistance in people with major depression, the clinical effectiveness of selected irreversible MAOIs for treatment-resistant depressive states, and changes in food preparation techniques and hygiene regulations that have increased the safety of MAOIs. This chapter reviews the clinical pharmacology and efficacy of MAOIs for treatment-resistant depression and provides practical advice on their safe and effective use for this specific indication.

Original languageEnglish (US)
Title of host publicationManaging Treatment-Resistant Depression
Subtitle of host publicationRoad to Novel Therapeutics
Number of pages30
ISBN (Electronic)9780128240670
ISBN (Print)9780128240687
StatePublished - Jan 1 2022


  • Isocarboxazid
  • Major depressive disorder (MDD)
  • Monoamine oxidase inhibitors (MAOIs)
  • Phenelzine
  • Tranylcypromine
  • Treatment-resistant depression

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Monoamine oxidase inhibitors for treatment-resistant depression'. Together they form a unique fingerprint.

Cite this